At the time of writing, Bicycle Therapeutics Plc ADR [BCYC] stock is trading at $25.56, up 3.73%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCYC shares have gain 13.60% over the last week, with a monthly amount glided 43.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs.
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on September 11, 2023, when B. Riley Securities upgraded its rating to a Buy. On July 28, 2022, Barclays initiated with a Overweight rating and assigned a price target of $30 on the stock. B. Riley Securities downgraded its rating to a Neutral and reduced its price target to $33 on April 13, 2022. In a note dated February 14, 2022, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $60 on this stock.
For the past year, the stock price of Bicycle Therapeutics Plc ADR fluctuated between $12.54 and $28.91. Currently, Wall Street analysts expect the stock to reach $70.5 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $25.56 at the most recent close of the market. An investor can expect a potential return of 175.82% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
According to Bicycle Therapeutics Plc ADR [NASDAQ:BCYC], the company’s sales were 27.07M for trailing twelve months, which represents an 67.58% jump. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.32 points at the first support level, and at 23.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.24, and for the 2nd resistance point, it is at 26.93.
Bicycle Therapeutics Plc ADR [BCYC] reported earnings per share of -$1.16 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.23/share, meaning a difference of $0.07 and a surprise factor of 5.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.26 per share as compared to estimates of -$1.17 per share, a difference of -$0.09 representing a surprise of -7.70%.
Ratios To Look Out For
It is important to note that Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] has a current ratio of 8.08. In addition, the Quick Ratio stands at 8.08 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 40.06, the price to book ratio is 2.92.
Transactions by insiders
Recent insider trading involved Lee Kevin, Chief Executive Officer, that happened on Jan 03 when 8703.0 shares were sold. Chief Business Officer, Crockett Nigel completed a deal on Jan 03 to sell 2643.0 shares. Meanwhile, Chief Technology Officer Skynner Michael sold 2643.0 shares on Jan 03.
